Biogen Inc.
www.biogen.com
Latest From Biogen Inc.
ARIBIO Counts On Multi-Modal Drug For Alzheimer's And Vascular Dementia
ARIBIO CEO tells Scrip how the South Korean biotech is aiming to develop a multi-modal drug for both Alzheimer’s disease and vascular dementia using its innovative platform technology, which can cut development periods and costs and better predict clinical trial success.
In Vivo’s Quick Guide To Gene Therapy
Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.
Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
Samsung Bioepis Targets Brazil With Brenzys
Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cancer
- Cardiovascular
- Immune Disorders
- Inflammation
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Biogen Idec Inc.
- Biogen Inc.
- Idec Pharmaceutical Corp.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
-
Michel Vounatsos, CEO
Jeffrey Capello, EVP, CFO
Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
Michael Ehlers, MD, PhD, EVP, R&D
Daniel Karp, EVP, Corp. Dev.
Chirfi Guindo, EVP & Head, Global Mktg. - Contact Info
-
Biogen Inc.
Phone: (617) 679-2000
225 Binney St.
Cambridge, MA 02142
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice